Switching cholinesterase inhibitors in patients with Alzheimer's disease

International Journal of Clinical Practice, Supplement

Volumn , Issue 127, 2002, Pages 64-72

  Emre, M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cholinesterase inhibitors; Donepezil; Galantamine; Rivastigmine; Switching

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMITRIPTYLINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CIMETIDINE; CYTOCHROME P450; DONEPEZIL; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; KETOCONAZOLE; NICOTINIC RECEPTOR; PAROXETINE; PHENYTOIN; QUINIDINE; RIFAMPICIN; RIVASTIGMINE; TACRINE;

ALLOSTERISM; ALZHEIMER DISEASE; BRADYCARDIA; BRAIN REGION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SLEEP DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; URINE INCONTINENCE; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NOOTROPIC AGENTS; TREATMENT FAILURE;

EID: 0036063226     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Selective loss of central cholinergic neurons in Alzheimer's disease
2. The cholinergic hypothesis of geriatric memory dysfunction
3. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
4. Ageing: The cholinergic hypothesis of cognitive decline
5. The cholinergic system in Alzheimer's disease
6. Donepezil treatment of Alzheimer's disease patients in California clinical practice: One-year follow-up
7. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology
8. Selectivity of cholinesterase inhibition
9. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan
10. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain
11. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase
12. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition
13. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
14. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
15. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
16. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
17. Galantamine in AD, a 6-month randomized placebo-controlled trial with a 6-month extension
18. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial
19. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine
20. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain
21. Cholinesterase inhibition in Alzheimer's disease: The pharmacologic basis of efficacy
22. Donepezil use in Alzheimer disease
23. Urinary incontinence: An unrecognised adverse effect with donepezil
24. A 5-month, randomised, placebo-controlled trial of galantamine in AD
25. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
26. Donepezil in dementia with Lewy bodies: Treatment and withdrawal
27. Possible association between donepezil and worsening Parkinson's disease
28. A 24-week, doubleblind, placebo controlled trial of donepezil in patients with Alzheimer's disease
29. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
30. Adverse effects associated with the use of donepezil in general practice in England
31. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
32. The effect of Exelon® on sleep in elderly healthy subjects
33. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials
34. Galantamine reduces slow wave sleep. Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence
35. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double blind, placebo-controlled international study
36. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man
37. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
38. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
39. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
40. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors
41. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
42. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR
43. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
44. Longterm tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities
45. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment
46. Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications
47. Evaluation of pharmacotherapeutic interventions in AD - Role of PET studies
48. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
49. Switching cholinesterase inhibitor therapy in Alzheimer's disease donepezil to rivastigmine, is it worth it?
50. Switching previous therapies for Alzheimer's disease to galantamine
51. Recommendations for prescribers